# A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

> **NCT06645665** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shenzhen Shenxin Biotechnology Co., Ltd** · enrollment: 240 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** Bivalent RSV Vaccine (IN006)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06645665
- **Lead sponsor:** Shenzhen Shenxin Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-11
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06645665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06645665, "A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06645665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*